Abstract: The network pharmacology and molecular docking were employed to investigate the active ingredients and pharmacological mechanism of Ganoderma lucidum. Taking oral availability and drug-like properties as evaluation indexes, active ingredients of Ganoderma lucidum were screened from the TCMSP data platform, potential targets of active ingredients were predicted in the Swiss target prediction platform, and GO analysis and KEGG Pathway enrichment analysis were conducted using the David database. The “active ingredients-target-pathway” network was constructed using Cytoscape 3.8.0 software to predict the pharmacological mechanism of the active ingredients of Ganoderma lucidum, and Sybyl-x 2.0 software was used to carry out the molecular docking verification. The results showed that 16 active ingredients were screened from polysaccharides, triterpenoids and steroids of Ganoderma lucidum, and 37 key targets, including AR, CYP17A1, CYP19A1, NR1H2, NRIH3, CYP17A1, CYP19A1, TDP1 and MAPT, were obtained by KEGG enrichment analysis. It involved 15 pathways, including Steroid hormone biosynthesis, Vascular smooth muscle contraction and Calcium signaling pathway. Molecular docking results showed that more than 60% of the active ingredients had good binding ability to the key targets, and the compound ergostere-7, 22-diene-3β-ol linoleate had the highest binding score to the target protein HSD17B2. The results of network pharmacological analysis showed that the active ingredients of Ganoderma lucidum mainly exerted therapeutic effects through vascular smooth muscle contraction, steroid hormone biosynthesis, insulin resistance and other pathways in cardiovascular and cerebrovascular diseases, tumors and other diseases.

Key words: Ganoderma lucidum, network pharmacology, molecular docking, active ingredients, pharmacological mechanism